Identification | Back Directory | [Name]
LDN-193189 HCl | [CAS]
1062368-62-0 | [Synonyms]
CS-1451 1062368-62-0 LDN-193189 HCl LDN-193189 4HCl LDN-193189 HCl USP/EP/BP LDN193189 (Hydrochloride) LDN-193189 HCL;LDN 193189 HCL 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyriMidin-3-yl)quinoline HCl LDN193189 hydrochloride, 98%, a selective BMP type I receptor kinases inhibitor LDN-193189 HCL;LDN 193189 HCL;LDN 193189 HYDROCHLORIDE;LDN-193189 HYDROCHLORIDE 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline hydrochloride (1:1) | [Molecular Formula]
C25H23ClN6 | [MDL Number]
MFCD17392570 | [MOL File]
1062368-62-0.mol | [Molecular Weight]
442.943 |
Chemical Properties | Back Directory | [Melting point ]
>240°C (dec.) | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
Methanol (Slightly), DMSO (Very Slightly, Heated) | [form ]
Solid | [color ]
Dark Orange | [CAS DataBase Reference]
1062368-62-0 |
Hazard Information | Back Directory | [Uses]
LDN-193189 HCl has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.
| [Biological Activity]
ldn193189 is a selective transcriptional activity morphogenetic protein (bmp) type i receptors inhibitor. it inhibits activin receptor-like kinase-2 (alk2) and alk3 with ic50 values of 5 nm and 30 nm, respectively [1].ldn193189 has been showed to inhibit bmp induced phosphorylation of smad signaling (smad1/5/8) and non-smad signaling including p38 and akt in c2c12 cells [2].pharmacological inhibition of bmp by ldn193189 has shown to prevent down-regulation of e-cadherin in response to bmp2 both in bronchial epithelial (beas2b) cells and in c57bl/6 mice. ldn193189 also inhibits the bmp-induced reduction of epithelial permeability at cellular level [3]. | [storage]
Store at -20°C | [References]
[1] yu pb, deng dy, lai cs, hong cc, cuny gd, bouxsein ml, hong dw, mcmanus pm, katagiri t, sachidanandan c, kamiya n, fukuda t, mishina y, peterson rt, bloch kd. bmp type i receptor inhibition reduces heterotopic [corrected] ossification. nat med. 2008 dec;14(12):1363-9. [2] boergermann jh1, kopf j, yu pb, knaus p. dorsomorphin and ldn-193189 inhibit bmp-mediated smad, p38 and akt signalling in c2c12 cells. int j biochem cell biol. 2010 nov;42(11):1802-7. [3] helbing t1, herold em, hornstein a, wintrich s, heinke j, grundmann s, patterson c, bode c, moser m. inhibition of bmp activity protects epithelial barrier function in lung injury. j pathol. 2013 sep;231(1):105-16. doi: 10.1002/path.4215. epub 2013 jul 10. |
|
Company Name: |
Shangchem Co., Ltd.
|
Tel: |
+86-21-68182121 |
Website: |
www.approvedhomemanagement.com/ShowSupplierProductsList14031/0.htm |
Company Name: |
NCE Biomedical Co.,Ltd.
|
Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
Website: |
www.approvedhomemanagement.com/ShowSupplierProductsList15748/0.htm |
|